VivoSeq
Neurology

Encephalitis

36

Pipeline Programs↗

8

Active Trials↗

14

Companies Involved↗

Encephalitis is a moderately active landscape with 36 programs across 14 companies. The most active players are Iovance Biotherapeutics, Inc., Horizon Therapeutics Ireland DAC, AbbVie. 3 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

56/100

Pipeline Velocity

11/100

Mech. Concentration

15/100

Completion Rate

92/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Iovance Biotherapeutics, Inc.

1 program

Phase 1H

Horizon Therapeutics Ireland DAC

1 program

Phase 2AbbVie logo

AbbVie

1 program

Phase 2A

Arialys Therapeutics

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2V

Veloxis Pharmaceuticals

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical8

Nivolumab

Bristol-Myers Squibb

Acyclovir

Bp Consulting, Inc

Clindamycin

Pfizer

Doxycycline

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Symptomatic Therapy

University Medical Centre Ljubljana

Phase 16

Aldesleukin

Iovance Biotherapeutics, Inc.

VRC-WEVVLP073-00-VP

National Institute of Allergy and Infectious Diseases (NIAID)

VEE 3526

DynPort Vaccine Company LLC, A GDIT Company

WN/DEN4Δ30 Vaccine

National Institute of Allergy and Infectious Diseases (NIAID)

LGT(TP21)/DEN4

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 213

Rituximab

Roche

Inebilizumab

Horizon Therapeutics Ireland DAC

Clarithromycin

AbbVie

Atovaquone

Glaxo Dba Glaxosmithkline

Pyrimethamine

Fondazione Matilde Tettamanti Menotti De Marchi Onlus

Phase 36

Valacyclovir

Glaxo Dba Glaxosmithkline

Tacrolimus

Veloxis Pharmaceuticals

Satralizumab

Roche

Immunoglobulins

CSL Behring

FSME-Immune

Sormland County Council, Sweden

Approved3

Dexamethasone

Aspen Global Incorporated

Methylprednisolone

Pfizer

TBE Virus Vaccine

Medical University of Vienna

Analysis

Modality Breakdown

65%

Small molecule

24 of 37 classified programs — the dominant modality here.

35%ALL OTHERSVaccine719%Monoclonal antibody411%Protein / enzyme25%

Small molecule leads; the ring shows all 37 classified programs, each share of the total. Modality classified for 100% of 46 pipeline programs.

Analysis

Trial Status

42

clinical trials

Completed24 · 57%
Unknown status8 · 19%
Recruiting4 · 10%
Active, not recruiting2 · 5%
Not yet recruiting2 · 5%
Withdrawn1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

42 trials

Tick-borne Encephalitis and Borrelial Antibodies in Serum
Recruiting·UUniversity Medical Centre Ljubljana·N/A·NCT03956446·80 enrolled
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
Recruiting·—·Phase 2·NCT06510283·10 enrolled
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
Recruiting·UUniversity of Utah·Phase 2·NCT04372615·116 enrolled
Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis)
Recruiting·TTongji Hospital·N/A·NCT06584045·250 enrolled
Safety, Reactogenicity and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered by Jet Injection
Active, not recruiting·PPharmaJet, Inc.·Phase 1·NCT06002503·46 enrolled
New Biomarkers in Auto-immune Encephalitis and Neurological Paraneoplastic Syndromes
Active, not recruiting·HHospices Civils de Lyon·N/A·NCT05728931·210 enrolled
A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Antibody-Associated Psychiatric Disease
Not yet recruiting·AArialys Australia Pty Ltd·Phase 2·NCT07093333·30 enrolled
First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers.
Not yet recruiting·—·Phase 1·NCT07377253·18 enrolled
Tick-borne Encephalitis and Possible Borrelial Serology
Completed·UUniversity Medical Centre Ljubljana·N/A·NCT03958058·690 enrolled
Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·N/A·NCT02856451·486 enrolled
Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
Completed·Pfizer logoPfizer·Phase 3·NCT04648241·165 enrolled
VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03879603·30 enrolled
A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis
Completed·—·Phase 1·NCT00259805·10 enrolled
Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00031486·91 enrolled
Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT02186626·28 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)